Dicot Pharma Dicot Pharma
På svenska

Phase 2a study Shows Positive Results

The proof of concept study demonstrated that the drug candidate LIB-01 improves erectile function — with sustained effect at week eight.

Strong development since the listing on Nasdaq First North

  • Home/
  • Investor Relations

Investor Relations

Dicot Pharma Raises SEK 231 Million

Dicot Pharma’s rights issue was oversubscribed and subscribed to approximately 134 percent. Through the rights issue and a directed share issue, the company will receive a total of approximately SEK 231 million before issue-related costs, to support the continued development of LIB-01.

Dicot Pharma aims to launch the drug candidate LIB-01 globally and become the first-choice treatment for erectile dysfunction and premature ejaculation. Our global ambition means we are gradually increasing international efforts in development, business, and communications.

At end of March 2026, Dicot Pharma had 16,750 shareholders. Since 2024, the stock has been listed on Nasdaq First North Stockholm.

IR Contact